Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.

Aihua Tan,Li Nong,Hongxue Wang,Yuxian Jia,Wuning Zhong,Fanghui Qin, Han Wang, Jing Tang,Yan Liu,Yongkui Lu

Cancer biology & therapy（2023）

引用 0|浏览1

暂无评分

摘要

Apatinib plus exemestane exhibited objective efficacy in patients with ER+/HER2- MBC who have failed multiple lines of treatment. The AEs of apatinib required close monitoring and most of patients were well tolerated.

查看译文

关键词

breast cancer,apatinib,receptor-positive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要